{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:20:59Z","timestamp":1775820059632,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.gastrohep.2017.05.017","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T18:46:13Z","timestamp":1501785973000},"page":"658-662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Mercedes","family":"Ramas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Donday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian G.","family":"McNicholl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2017.05.017_bib0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection \u2013 the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0220","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/00365521.2015.1092577","article-title":"In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy","volume":"51","author":"Di Giulio","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0225","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/1751-2980.12271","article-title":"Susceptibility of Helicobacter pylori to antibiotics in Chinese patients","volume":"16","author":"Bai","year":"2015","journal-title":"J Dig Dis"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0230","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(84)91816-6","article-title":"Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration","volume":"1","author":"Marshall","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0235","first-page":"A64","article-title":"European Registry on H. pylori management (HPEUREG): first-line treatments and interim analysis of 11,272 patients","volume":"3","author":"Mcnicholl","year":"2015","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0240","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3904\/kjim.2015.30.6.801","article-title":"Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0245","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5061640","article-title":"Efficacy of 7-day and 14-day triple therapy regimens for the eradication of Helicobacter pylori: a comparative study in a cohort of Romanian patients","author":"Arama","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0250","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/1319-3767.161647","article-title":"Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection","volume":"21","author":"Alsohaibani","year":"2015","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0255","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.2174\/13816128113196660731","article-title":"Strategy for the treatment of Helicobacter pylori infection","volume":"20","author":"Shiota","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0260","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1365-2036.2011.04887.x","article-title":"Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough","volume":"34","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0265","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0270","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","article-title":"H. pylori antibiotic resistance: prevalence, importance, and advances in testing","volume":"53","author":"Megraud","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0275","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.3748\/wjg.v20.i30.10338","article-title":"Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance","volume":"20","author":"Molina-Infante","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0280","first-page":"257","article-title":"In vitro and in vivo evaluation of L\/105, a new topical intestinal rifamycin","volume":"5","author":"Venturini","year":"1986","journal-title":"Chemioterapia"},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2017.05.017_bib0285","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0290","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jinf.2004.05.019","article-title":"Rifaximin \u2013 a novel antimicrobial for enteric infections","volume":"50","author":"Huang","year":"2005","journal-title":"J Infect"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0295","first-page":"141","article-title":"[Rifaximin]","volume":"17","author":"Gobernado","year":"2004","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0300","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","article-title":"Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections","volume":"3","author":"Gerard","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2017.05.017_bib0305","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000089788","article-title":"Eradication of Helicobacter pylori: are rifaximin-based regimens effective?","volume":"73","author":"Gasbarrini","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0310","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0210-5705(03)70485-3","article-title":"[Evaluation of Helicobacter pylori susceptibility to rifaximin]","volume":"27","author":"Quesada","year":"2004","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0315","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000090330","article-title":"Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study","volume":"24","author":"Gasbarrini","year":"2006","journal-title":"Dig Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2017.05.017_bib0320","first-page":"S10","article-title":"Rifaximin a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety","volume":"5","author":"Williams","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0325","first-page":"2177","article-title":"[Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders]","volume":"145","author":"Gasztonyi","year":"2004","journal-title":"Orv Hetil"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00002018-200629030-00004","article-title":"Safety and tolerability of the antibacterial rifaximin in the treatment of travellers\u2019 diarrhoea","volume":"29","author":"Ericsson","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0335","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000061963","article-title":"Bismuth compounds for eradication of Helicobacter pylori: pharmacology and safety","volume":"11","author":"Scarpignato","year":"1999","journal-title":"Prog Basic Clin Pharmacol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0340","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1111\/j.1572-0241.2000.03349.x","article-title":"Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials","volume":"95","author":"Laine","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0345","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1046\/j.1365-2036.2000.00844.x","article-title":"Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori","volume":"14","author":"Gisbert","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0350","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.5897\/AJB2010.000-3015","article-title":"Increasing trend of Metronidazole resistance in the treatment of Helicobacter pylori infection. A global challenge","volume":"9","author":"Buta","year":"2010","journal-title":"Afr J Biotechnol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0355","first-page":"222","article-title":"In vitro antibacterial activity of rifaximin against Campylobacter pylori (Campylobacter pyloridis)","volume":"1","author":"Mignini","year":"1989","journal-title":"J Chemother"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0360","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF01982198","article-title":"In vitro activity of rifaximin against Helicobacter pylori","volume":"13","author":"Megraud","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0365","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jac\/35.4.545","article-title":"The susceptibility of Helicobacter pylori to the rifamycin, rifaximin","volume":"35","author":"Holton","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0370","first-page":"105","article-title":"A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori","volume":"3","author":"Dell\u2019Anna","year":"1999","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0375","first-page":"105","article-title":"Rifaximin and Helicobacter pylori eradication","volume":"1","author":"De Giorgio","year":"1997","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0380","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3346\/jkms.2011.26.6.785","article-title":"Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial","volume":"26","author":"Choi","year":"2011","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0385","first-page":"85","article-title":"[Rifaximin in combined treatment of the Helicobacter pylori infection in childhood]","author":"Nizhevich","year":"2011","journal-title":"Eksp Klin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0390","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2036.1999.00555.x","article-title":"A systematic review of Helicobacter pylori eradication therapy \u2013 the impact of antimicrobial resistance on eradication rates","volume":"13","author":"Houben","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0395","first-page":"144A","article-title":"Effect of rifaximin, a new non absorbed antibiotic, in the treatment of Helicobacter pylori infection","volume":"56","author":"Pretolanis","year":"1993","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000238165","article-title":"Pharmacokinetics of L\/105, a new rifamycin, in rats and dogs, after oral administration","volume":"29","author":"Venturini","year":"1983","journal-title":"Chemotherapy"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0405","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF01296271","article-title":"Influence of meal weight and caloric content on gastric emptying of meals in man","volume":"29","author":"Moore","year":"1984","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0410","first-page":"R959","article-title":"Intrinsic emptying pattern of the human stomach","volume":"246","author":"Smith","year":"1984","journal-title":"Am J Physiol"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0415","first-page":"1204","article-title":"Gender-related differences in gastric emptying","volume":"28","author":"Datz","year":"1987","journal-title":"J Nucl Med"},{"key":"10.1016\/j.gastrohep.2017.05.017_bib0420","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/gut.33.5.592","article-title":"Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus","volume":"33","author":"Munoz","year":"1992","journal-title":"Gut"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057051730153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057051730153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T19:41:51Z","timestamp":1659296511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021057051730153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S021057051730153X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2017.05.017","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2017.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U., AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}